Permax

Known as: Celance, Parkotil, Lilly Brand of Pergolide 
 

Topic mentions per year

Topic mentions per year

1994-2010
01219942010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
BACKGROUND Although ongoing cohort studies offer a unique opportunity to apply existing information collected prospectively to… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2008
Review
2008
Recent voluntary withdrawal of the ergoline-derivative Alzheimers' drug Pergolide (Permax) resulting from demonstrated risk of… (More)
Is this relevant?
2006
2006
This chapter contains information about all the therapeutically used ergot alkaloids and their manufacture. Not all such… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional… (More)
Is this relevant?
2004
2004
One of the most disabling problems in males suffering from advanced Parkinson's disease (PD) is complex sexual dysfunction. The… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
An 8-month multicentre prospective randomized study aimed at comparing the effects of dopamine receptor agonists pramipexole (PPX… (More)
Is this relevant?
2003
2003
The widening array of drugs available for treating people with Parkinson’s disease (PD) raises several questions, e.g. when… (More)
Is this relevant?
2001
2001
UNLABELLED The effect of Permax (pergolide mesylate), a dopamine agonist, was assessed in an individual with traumatic brain… (More)
Is this relevant?
1998
1998
OBJECTIVE AND IMPORTANCE We present a case of a giant prolactinoma with a falsely low serum prolactin concentration determined by… (More)
Is this relevant?
1994
1994
Pergolide (Permax, LY127809, CAS 66104-23-2) a dopamine agonist for the treatment of Parkinson's disease, was evaluated for… (More)
Is this relevant?